ong-term aspirin therapy as a predictor of decreased susceptibility to SARSCoV-2 infection in aspirin-exacerbated respiratory disease

Phase 1

• Conditions: aspirin-exacerbated respiratory disease; MedDRA version: 25.1Level: LLTClassification code: 10003534Term: Aspirin-sensitive asthma Class: 10038738; MedDRA version: 25.1Level: LLTClassification code: 10075084Term: Aspirin-exacerbated respiratory disease Class: 100000004855; Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

• Registration Number: CTIS2024-514602-31-00
• Lead Sponsor: niwersytet Jagiellonski Collegium Medicum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-05-24
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

INCLUSION CRITERIA FOR AERD PATIENTS:* signed informed consent form * 18-70 years old AERD patients with baseline FEV1 of at least 70% of the predicted value on the challenge/desensitization day * no pregnancy, higly effective contraception must be used, INCLUSION CRITERIA FOR HEALTHY CONTROL: * signed informed consent form * 18-70 years old and healthy condition * no asthma

Exclusion Criteria

failure of the circulatory and respiratory system, liver, kidneys and other vital organs, diabetes, cancer, systemic diseases of connective tissue, infectious diseases, coagulation disorders, active peptic ulcer disease, any active bleeding process., Use of drugs that interact with aspirin, use of intoxicants, alcohol abuse, active and passive smoking, pregnancy, lactation, hypersensitivity to the active substance or any of the excipients

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified